Federal government to fund safer drug supply projects in Vancouver, Victoria

The federal government is providing more than $15 million over the next four years to create four safer drug supply projects for people at risk of overdoses in British Columbia.

The projects will provide pharmaceutical-grade medication as an alternative to the toxic illegal opioid supply currently in circulation, in an attempt to reduce illicit drug overdose deaths, according to a government statement. The safe supplies will be located in Vancouver and Victoria and will provide people with opioid use disorder with a safer, medical alternative from a licensed prescriber.

“Street supply opioids have been tainted by fentanyl and benzodiazepines, making them fatal. The number of preventable deaths have steadily increased and evidence shows that one of the surest ways to save lives is through replacement therapy with a safe supply,” Vancouver Centre MP Hedy Fry said in the statement.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below